Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Janice Hopkins Tanne
| The first 150 words of the full text of this article appear below. |
A US randomised, placebo controlled, double blind trial to evaluate oestrogen and progestogen in postmenopausal women was stopped early by the Women's Health Initiative because health risks exceeded health benefits by a small margin.
It is the first trial to examine whether continuous oestrogen plus progestogen has a favourable or unfavourable effect on coronary heart disease and overall risks and benefits in healthy women.
JAMA has already posted the article on its website (www.jama.com). The article will then be published in the 17 July issue together with an editorial that says, "do not use estrogen/progestin to prevent chronic disease" (JAMA 2002;288:321-33, 366-8).
Lead author Dr Jacques Rossouw, acting director of the study for the
National Heart, Lung, and Blood Institute, cautioned, "This is not an
urgent situation like a drug recall. The average risk to the individual
woman is one tenth of 1% per year for breast cancer
Read all Rapid Responses